WuXi AppTec Announces Annual Results and Dividend for Year Ended 31 December 2025
WuXi AppTec Co., Ltd. (02359.HK), a leading life‑sciences services provider listed on the Hong Kong Stock Exchange, released its audited financial statements for the year ended 31 December 2025 at 23:08 GMT on 23 March 2026. The company reported a significant rise in earnings and revenue, prompting an announcement of a cash dividend for shareholders.
Financial Highlights
| Item | 2025 | 2024 | % Change |
|---|---|---|---|
| Revenue | HKD 49.67 billion | HKD 41.11 billion | +21.1 % |
| Net profit | HKD 6.31 billion | HKD 3.51 billion | +80.2 % |
| Earnings per share (EPS) | HKD 6.31 | HKD 3.51 | +80.2 % |
The reported earnings per share of HKD 6.31 represent an 80 % increase over the prior year, aligning with analyst expectations of approximately HKD 6.31 EPS for the full year. Revenue growth of 21 % was driven by higher sales in both biopharmaceutical development and diagnostic services, with the company reporting a 24.5 % increase in quarterly sales for the most recent fiscal quarter.
Dividend Declaration
On 23 March 2026, the Board declared a cash dividend of HKD 0.60 per share, to be paid to shareholders of record as of 30 March 2026. This dividend represents a payout ratio of roughly 30 % of the reported net profit, reflecting the company’s strong liquidity position and its commitment to returning value to investors.
Corporate Governance Updates
Alongside the financial results, WuXi AppTec announced several governance matters:
- Re‑election of Directors – The Board presented proposals for the re‑election of both executive and non‑executive directors, including independent non‑executive directors, for the upcoming annual general meeting.
- Share Award Scheme Amendments – Proposed amendments to the rules of the 2025 H‑Share Award and Trust Scheme were submitted, aiming to align incentive plans with long‑term performance metrics.
- Remuneration Committee – The Terms of Reference for the Remuneration and Appraisal Committee were released, detailing the committee’s responsibilities and appointment procedures.
These items will be voted on at the forthcoming shareholders’ meeting.
Market Reaction
The announcement coincided with a broader sell‑off in the Hong Kong market, where the Hang Seng Index fell 894 points (3.5 %) to 24,382. Despite the overall market decline, WuXi AppTec’s shares traded near the 52‑week high of HKD 129.90, reflecting investor confidence in the company’s robust earnings growth and dividend policy.
Outlook
Analysts project that WuXi AppTec will continue to benefit from expanding demand for biopharmaceutical development services. The company’s strategic investments in technology platforms and global partnerships are expected to sustain revenue growth and profitability in the coming years.
